Systemic Consolidation Therapy After Primary Chemoradiation Therapy for Locally Advanced Cervical Cancer

Inclusion Criteria: * patients who underwent three cycles of concurrent chemoradiation therapy with paclitaxel and carboplatin for non-small cell type cervical cancer stage IB2, bulky size (\>4cm) IIA,IIB-IVA * above 20 years * GOG performance status 0-2 * Informed consent * Platelet\>100K, Hb\> 10.0 g/dl, ANC\>1500/mm3, Cr \<1.25\*upper normal limit, bilirubin\<1.5mg/dl, AST \& ALT\<\*3 upper normal limit * Expected life \> 6 months Exclusion Criteria: * Peripheral neurotoxicity \> NCI CTCAE grade 2 * Sever infection * Previous history with chemotherapy or radiation therapy * Pleural effusion, pericardial effusion, and ascites which could cause dyspnea \> NCI grade 2 * Paraaortic lymph node metastasis * Allergy with platinum * Previous history of atrial or ventricular arrhythmia or congestive heart failure * Uncontrolled infection, diabetes mellitus, hypertension, ischemic heart disease, myocardiac infarct within 6 months * Severe disease such as acute or chronic renal failure and acute cerebral infarct, cerebral hemorrhage, recurrent hepatitis, liver cirrhosis, unknown fever above 39 degrees centigrade